Hereditary Influences on Pulmonary Fibrosis Trajectories

N/AActive Not RecruitingNCT07580053

Istituto Clinico Humanitas250 enrolled

Overview

The SHIFT (Hereditary Influences on Pulmonary Fibrosis Trajectories) study is a prospective, multicenter, observational cohort study designed to investigate familial pulmonary fibrosis (FPF) within the Italian population.

Familial pulmonary fibrosis (FPF) is a genetically driven subset of fibrosing interstitial lung diseases (ILDs) characterised by heterogeneous phenotypes, variable clinical trajectories, and limited evidence to guide prognosis and treatment. Although antifibrotic therapies are effective in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), data in FPF, particularly from European populations, remain scarce. The SHIFT (Hereditary Influences on Pulmonary Fibrosis Trajectories) study aims to prospectively characterize disease progression, treatment response, and outcomes in a national Italian cohort. SHIFT is a prospective, multicenter, observational cohort study enrolling adults (≥18 years) with ILD on high-resolution computed tomography and genetic findings consistent with FPF. Participants are recruited from specialized ILD referral centers across Italy and followed every 6 months for up to 5 years. Diagnostic attribution is standardized through multidisciplinary discussion using a structured confidence framework. All treatments are prescribed according to routine clinical practice. The primary endpoint is annual relative decline in forced vital capacity (FVC). Secondary endpoints include longitudinal changes in diffusing capacity (DLCO), treatment effectiveness and safety, mortality, transplant-free survival, cancer incidence, and genotype-phenotype and genotype-treatment response associations. Longitudinal data will be analyzed using mixed-effects models, and time-to-event outcomes using survival methods. Multivariable analyses and sensitivity analyses will address confounding.

Study Type

OBSERVATIONAL

Enrollment

250

Conditions

Interstitial Lung Disease Due to Systemic Disease (Telomere Biology Disorder)Idiopathic Pulmonary Fibrosis (IPF)Telomere Disease Progressive Pulmonary Fibrosis Familial Pulmonary Fibrosis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * A HRCT scan consistent with ILD diagnosis * Age over 18 years old * A genetic test proved variant or a polymorphism consistent with a diagnosis of FPF * Ability to give informed consent for the inclusion in the study Exclusion Criteria: * Patients unable to perform pulmonary function tests

Locations (1)

Francesco Amati

Rozzano, Italy, Italy

Outcomes

Primary Outcomes

annual relative FVC decline over the observation period

The annual relative decline is defined as the difference between the final and the initial FVC value divided by the initial value, and it will be calculated for each year and for the entire follow-up period.

Time frame: Annual for 5 years

Secondary Outcomes

relative reduced annual FVC decline when compared to FPF patients treated with immunomodulator agents and FPF patients not treated in a 5-years period of FU.

Time frame: 5 years

mortality

Time frame: 5 years

Annual relative DLCO decline

Annual relative DLCO decline: The annual relative decline is defined as the difference between the final and the initial DLCO value divided by the initial value, and it will be calculated for each year and for the entire follow-up period.

Time frame: 5 years

incidence of lung and non-lung cancer

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.